857127 | 17:0 Lyso PA

1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt)


Powder

Size SKU Packaging Price
25mg 857127P-25mg 857127P-25mg 1 x 25mg $316.50
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

17:0 Lyso PA

17:0 Lyso PA

1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt)

Hygroscopic
Yes
Light Sensitive
No
Molecular Formula
C20H40O7PNa
Percent Composition
C 53.80%, H 9.03%, Na 5.15%, O 25.08%, P 6.94%
Purity
>99% LPA; may contain up to 10% of the 2-LPA isomer
Stability
1 Years
Storage Temperature
-20°C
CAS Number
799268-66-9
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
446.491
Exact Mass
446.241
Synonyms
<p>heptadecanoyl lysophosphatidic acid1-heptadecanoyl-sn-glycero-3-phosphate (sodium salt)PA(17:0/0:0)17:0 LPA110679</p>

Juin A, Spence HJ, Martin KJ, McGhee E, Neilson M, Cutiongco MFA, Gadegaard N, Mackay G, Fort L, Lilla S, Kalna G, Thomason P, Koh YWH, Norman JC, Insall RH, Machesky LM. N-WASP Control of LPAR1 Trafficking Establishes Response to Self-Generated LPA Gradients to Promote Pancreatic Cancer Cell Metastasis. Dev Cell. 2019 Nov 18;51(4):431-445.e7. doi: 10.1016/j.devcel.2019.09.018. Epub 2019 Oct 24.

PubMed ID: 31668663

Kraemer M, Mao G, Hammill C, Yan B, Li Y, Onono F, Smyth SS, Morris AJ. Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid. J Lipid Res. 2019 Sep 4. pii: jlr.M093096. doi: 10.1194/jlr.M093096. [Epub ahead of print]

PubMed ID: 31484695

Pan J, Tao C, Cao C, Zheng Q, Lam SM, Shui G, Liu X, Li K, Zhao J, Wang Y. Adipose lipidomics and RNA-Seq analysis revealed the enhanced mitochondrial function in UCP1 knock-in pigs. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1375-1383. doi: 10.1016/j.bbalip.2019.06.017. Epub 2019 Jul 2.

PubMed ID: 31271850

van der Aar E, Desrivot J, Dupont S, Heckmann B, Fieuw A, Stutvoet S, Fagard L, Van de Wal K, Helmer E. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. J Clin Pharmacol. 2019 Apr 23. doi: 10.1002/jcph.1424. [Epub ahead of print]

PubMed ID: 31012984

Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, Fujiwara Y. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19. doi: 10.1074/jbc.M109.003194. Epub 2009 Apr 14.

PubMed ID: 19366702

Yang JS, Kim JY, Lee JC, Moon MH. Investigation of lipidomic perturbations in oxidatively stressed subcellular organelles and exosomes by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2019 Sep 27;1073:79-89. doi: 10.1016/j.aca.2019.04.069. Epub 2019 May 1.

PubMed ID: 31146839

Yagi T, Shoaib M, Kuschner C, Nishikimi M, Becker LB, Lee AT, Kim J. Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer. Cancers (Basel). 2019 Apr 11;11(4). pii: E520. doi: 10.3390/cancers11040520.

PubMed ID: 30979045

Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, Fujiwara Y. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19. doi: 10.1074/jbc.M109.003194. Epub 2009 Apr 14.

PubMed ID: 19366702